Pelago Bioscience AB

We are attending Europe's largest partnering event, BIO-Europe 2024 as a part of Sweden’s vibrant life science ecosystem. Our CEO, Michael Dabrowski, along with Senior Regional Sales Manager Marianne Alksnis and Head of Sales Magnus Lejelöv, will be at the Swedish Pavilion and look forward to meeting you. Come say hello and discover we can help you gain early confidence in your drug discovery projects. After a day at BIO-Europe, we invite you to keep the conversation going at our nearby facility. Enjoy a guided tour of our lab, explore the latest developments at the Home of CETSA®, and connect with industry peers over refreshments. Check out event highlights and RSVP for our Open House on our website: https://hubs.la/Q02WgyqC0 #SwedenBio #DrugDiscovery #BioEurope2024

Will you be attending the 7th Annual TPD & Induced Proximity Summit 2024 in Boston, MA, from October 28-31? 💡Visit us at Booth 9 to meet our team: Brian W. J., Stephen Kosteski and Michael Dabrowski. Discover how our services can bring certainty to your drug discovery projects. CETSA® (Cellular Thermal Shift Assay) is an effective method for studying interactions between small molecules and their protein targets, particularly useful in targeted protein degradation (TPD) as it improves insights from degradation profiles. CETSA can be conducted in cell lysates and intact cells without modifying compounds, proteins, or cellular environments. 👀 Don't miss our poster presentation and discover why CETSA is key to elucidate the connections between molecular dynamics and cellular effects. 🖼️ Poster Session 19 📅 29 October 🕛 3:00 PM 🔗 Unlock deeper insights into biological relevance: https://hubs.la/Q02VGPp-0 #TPD2024 #proteins #drugdiscovery #degradation

We are approaching the end of an exciting and inspiring HUPO2024 meeting in Dresden. CETSA® with MS detection (TPP or PISA) does not need any introduction to this crowd. Lots of data and attention at seminars and only today there are more than a dozen posters where our method has been instrumental. One of these posters titled "Igniting Drug Discovery - pushing CETSA-MS to scale” summarize some of the nice work carried out by one of our licensees, Bayer here represented by Jana Flegel and Shiva Ahmadi from the Wuppertal site. #HUPO #HUPO2024 #drugdiscovery

We’re excited to share that Daniel Martinez Molina and Alexey Chernobrovkin will be heading to the Human Proteome Organization (HUPO) World Congress in Dresden from October 20-24! 🧬✨ Even more exciting – Alexey will be giving a talk at a lunch seminar sponsored by Thermo Fisher. 🗓️ Monday, 21 October, 2024 🕛 12:15 – 13:15 CEST 📍 International Congress Center Dresden – Conference room 5+6 🎤 Title: Boosting throughput of thermal proteome profiling Thermo Fisher has been a fantastic partner, and we’re excited to share how we’re using the Orbitrap Astral mass-spectrometer in our daily work. If you're going to be at HUPO, definitely swing by and check out Alexey's session. It’s a great chance to see the tech in action and chat with us. Hope to see you there! #HUPO2024 #MassSpec #Proteomics #ThermoFisher #ScienceInAction

Really great seeing the Pelago Bioscience AB team represented by Isabel M Caballero PharmD PhD and Mary Spanou during the event arranged by British Pharmacological Society at the AstraZeneca facilities in Cambridge! Looking forward to a couple of days of discussing how Pelago Bioscience AB can help companies and academia understanding their targets.

Pelago Bioscience AB is sponsoring British Pharmacological Society Emergence of Irreversible Modulation in Drug Discovery Meeting in Cambridge UK, on October 16-17. 💡 Struggling to prioritize the right compound? Our new service, Unbiased Selectivity Profiling, can help you prioritize the right compounds, enabling better decision-making in your drug discovery process. 👀 Don't miss our presentations! Learn more about Selectivity Profiling: 🎤 Speaker: Isabel M Caballero PharmD PhD Talk Title: The Cellular Thermal Shift Assay: How Assessment of Target Engagement Helps Identify Early Liabilities 📅: 17 October 🕘: 10:10–10:30 AM 🖼️ Poster Sessions: 📅 16 October 🕛 12:05–13:30 Lunch & Poster Session 🕒 15:05–15:30 Coffee Break 📅 17 October 🕛 12:05–13:05 Lunch & Poster Session 🕒 15:00–15:30 Break & Refreshments Be sure to visit us at Booth 9 and meet Mary Spanou our Regional Sales Manager for the UK, along with Magnus Lejelöv and Isabel M Caballero PharmD PhD. They’re eager to connect and discuss how we can support your drug discovery needs! 🤔 Curious about our Unbiased Selectivity Profiling service? 🔗 Learn more here: https://hubs.la/Q02TdgGx0 🎥 Check out the video below to learn how we can help you gain early confidence in your drug discovery project. #DrugDiscovery

For #drughunters looking at off-target effects, promiscuity, and liability in the #proteomics space... look no further than our new Standard Selectivity Profiling service interrogating a whopping 5000 proteins with a turnaround time in 10 days leveraging #cetsa (no need for labeling or tags). See below or reach out to Pelago Bioscience AB and schedule an overview on how we can help advance your #drugdiscovery research.

ELRIG UK Drug Discovery 2024 is just around the corner, and our team is excited to meet you! Be sure to stop by our booth, F07, and meet Mary Spanou our new Regional Sales Manager for the UK, along with the rest of the team—Erwin Daniel Brenndörfer, Isabel M Caballero PharmD PhD and Marianne Alksnis Don’t miss Isabel’s talk, 'The Cellular Thermal Shift Assay: How Assessment of Target Engagement Helps Identify Early Liabilities,' where she’ll share valuable insights. 📅 October 2nd 🕙 2:30 - 2:40 PM 📍Auditorium 4 Track: Small molecules beyond Rule of 5 – Modalities, Developments and Learnings Check out our poster presentation to learn about our new service, Standard Selectivity Profiling (Poster Number: 8). 📅 October 2nd 🕝 5.00 - 5:30 PM 📅 October 3nd 🕝 1:00 - 1:30 PM Feel free to reach out to Mary—you may have more in common than you think when it comes to your projects!" https://hubs.la/Q02RD1Wn0 #ELRIGDD24 #DrugDiscovery

🎯 Headed to Discovery on Target 2024? Don’t miss out on Stina Lundgren’s talk, where she’ll dive into "How CETSA® Can Unlock Targeted Drug Discovery on p53." 📅 October 1 ⏰ 2:20 - 2:35 PM Track: C3A (Small Molecules for Cancer Targets). Plus, swing by our poster, A44, during the refreshment breaks (Oct 1 & 2) and check out the insights on "Unbiased Selectivity Profiling with CETSA & MS detection." And of course, meet our team—Stina Lundgren, Brian W. J., and Stephen Kosteski will be at booth 409! Come say hi and hear all about our new Standard Selectivity Profiling Service in person. Can’t wait? Get a sneak peek here: https://hubs.la/Q02Rtrf90 #DoT2024 #drugdiscovery

We’re happy to introduce our latest addition to our service portfolio; Standard Selectivity Profiling. Whether you are a pharmaceutical company, biotech company or academia – the struggle to identify early liabilities, to proceed with the safest lead candidates, is the same. In just 10 days we’ll enable you to prioritize the right compounds. Want to learn more?  https://lnkd.in/dM_Giz8D #drugdiscovery #newservice